Everand Logo

Welcome to Everand!

  • STAT

    With eyes on Gilead, lawmakers want details on how HHS reviews possible patent infringement

    After a ruckus over a pricey Gilead Sciences drug for HIV, lawmakers want details on how HHS reviews possible patent infringement.
    by Ed Silverman Jun 18, 2019 3 minutes
    Source: Alex Wong/Getty Images

    A pair of lawmakers has asked the Government Accountability Office to review how the U.S. Department of Health and Human Services manages patents and licenses for medicines that were discovered, at least in part, with taxpayer dollars.

    The move by Sen. Debbie Stabenow (D-Mich.) and Rep. Elijah Cummings (D-Md.) follows a ruckus over a pricey Gilead Sciences () pill for treating and preventing HIV and the role federal government may have played in discovering the medicine, which is

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks